Editing Filgrastim (section)

==Adverse effects==
The most commonly observed adverse effect is mild bone pain after repeated administration,<ref name="pmid28423916">{{cite journal | vauthors = Moore DC, Pellegrino AE | title = Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management | journal = The Annals of Pharmacotherapy | volume = 51 | issue = 9 | pages = 797–803 | date = September 2017 | pmid = 28423916 | doi = 10.1177/1060028017706373 | s2cid = 33032446 }}</ref> and local skin reactions at the site of injection.<ref name="Neupogen FDA label">{{cite web | title=Neupogen- filgrastim injection, solution | website=DailyMed | date=15 November 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193 | access-date=20 December 2019 | archive-date=25 November 2020 | archive-url=https://web.archive.org/web/20201125222325/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193 | url-status=live }}</ref> Other observed adverse effects include serious allergic reactions (including a rash over the whole body,<ref name="pmid19614649">{{cite journal | vauthors = Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S | title = Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption | journal = The British Journal of Dermatology | volume = 161 | issue = 3 | pages = 717–719 | date = September 2009 | pmid = 19614649 | doi = 10.1111/j.1365-2133.2009.09371.x | s2cid = 2655192 }}</ref> shortness of breath, wheezing, dizziness, swelling around the mouth or eyes, fast pulse, and sweating), [[ruptured spleen]] (sometimes resulting in death),<ref name="pmid8450676">{{cite journal | vauthors = Zimmer BM, Berdel WE, Ludwig WD, Notter M, Reufi B, Thiel E | title = Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies | journal = Leukemia Research | volume = 17 | issue = 3 | pages = 277–283 | date = March 1993 | pmid = 8450676 | doi = 10.1016/0145-2126(93)90012-a }}</ref> [[Pulmonary alveolus|alveolar]] [[Bleeding|hemorrhage]], [[acute respiratory distress syndrome]], and [[hemoptysis]].<ref name="Neupogen FDA label" /> Severe [[Sickle cell crisis|sickle cell crises]], in some cases resulting in death, have been associated with the use of filgrastim in people with sickle cell disorders.<ref name="Neupogen FDA label" />